Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have become indispensable for both patients and clinicians in managing type 2 diabetes mellitus (T2DM) and obesity. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.